GlassScriptPhysician profile
David Hammack
NPI 1497006043
$5,208.60
in general payments reported to CMS, 2019-2025
33 companies · $787 in 2025
The $787 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $355 · 2023: $2,247 · 2024: $1,591 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,625.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.74 | 2021-2025 | |
| Pfizer INC. | $539.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $477.66 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Astellas Pharma US INC | $465.91 | 2021-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $437.47 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $368.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $317.36 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.61 | 2021-2025 | Tradjenta, Synjardy, Jardiance |
| Exact Sciences Corporation | $155.51 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $131.31 | 2023-2025 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $129.18 | 2023-2024 | Rexulti, Nuedexta |
| Amgen INC. | $105.43 | 2023-2025 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $100.16 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $84.03 | 2021-2025 | Airsupra, Breztri, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $77.85 | 2023-2025 | Eliquis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $76.82 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.32 | 2022-2023 | Trulance, Xifaxan |
| Insulet Corporation | $70.31 | 2024-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $65.26 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $52.73 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $50.73 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $36.15 | 2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.19 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $33.90 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $31.38 | 2024 | |
| Ibsa Pharma INC. | $28.73 | 2023 | Tirosint, Licart |
| Phathom Pharmaceuticals, INC. | $19.23 | 2025 | Voquezna |
| Amarin Pharma, INC. | $18.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.89 | 2023 | |
| Amneal Pharmaceuticals LLC | $17.53 | 2025 | Unithroid |
| Boston Scientific Corporation | $16.33 | 2024 | Watchman Flx |
| Almatica Pharma LLC | $14.60 | 2025 | Teriparatide, Loreev Xr |
| Bridgebio Pharma, INC. | $13.63 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hammack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.